(Q35102974)

6 August 2017

1 reference

title

Benefits and burdens of placebos in psychiatric research (English)

1 reference

6 August 2017

0 references

Scott Y H Kim

1

1 reference

6 August 2017

publication date

9 April 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

171

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

13-18

1 reference

National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders

6 August 2017

cites work

1 reference

12 December 2020

Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database

1 reference

12 December 2020

Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation

1 reference

12 December 2020

The ethical analysis of risk

1 reference

12 December 2020

Cost utility analysis of maintenance treatment for recurrent depression.

1 reference

12 December 2020

World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects

1 reference

12 December 2020

False hopes and best data: consent to research and the therapeutic misconception

1 reference

12 December 2020

Placebo orthodoxy in clinical research. II: Ethical, legal, and regulatory myths

1 reference

12 December 2020

The continuing unethical use of placebo controls

1 reference

12 December 2020

Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol

1 reference

12 December 2020

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

1 reference

12 December 2020

1 reference

12 December 2020

The rationale and ethics of medication-free research in schizophrenia

1 reference

12 December 2020

Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings

1 reference

12 December 2020

A reevaluation of the exclusion criteria used in antidepressant efficacy trials

1 reference

12 December 2020

Modelling the cost effectiveness of antidepressant treatment in primary care

1 reference

12 December 2020

Suicide risk in placebo-controlled studies of major depression

1 reference

12 December 2020

The ethics of placebo-controlled trials--a middle ground

1 reference

12 December 2020

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

1 reference

12 December 2020

Perceptions of cancer patients and their physicians involved in phase I trials

1 reference

12 December 2020

Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database

1 reference

12 December 2020

The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective

1 reference

12 December 2020

Withholding proven treatment in clinical research

1 reference

12 December 2020

The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals

1 reference

12 December 2020

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression

1 reference

12 December 2020

Cost-utility analysis in depression: the McSad utility measure for depression health states

1 reference

12 December 2020

Placebo control groups in randomized treatment trials: a statistician's perspective

1 reference

12 December 2020

10.1007/S00213-003-1458-2

Identifiers

DOI

1 reference

6 August 2017

1 reference